Back to Results

Zomedica Corp (ZOMDF)

Zomedica Corp. is a healthcare company focused on veterinary health, with an emphasis on addressing unmet needs in clinical practices that serve companion animals. The company develops and commercializes diagnostic and therapeutic products, including the TRUFORMA point-of-care diagnostic platform, TRUVIEW digital cystoscopy platform, and VetGuardian remote vital-signs monitoring system. Its therapeutic portfolio also includes the PulseVet electrohydraulic shockwave therapy platform and the Assisi Loop family of devices, such as Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop, which are designed to deliver targeted pulsed electromagnetic field energy for pain and inflammation management. Formerly known as Zomedica Pharmaceuticals Corp., the company adopted its current name in October 2020 and is headquartered in Ann Arbor, Michigan. Zomedica common stock trades on OTC Markets under the symbol ZOMD.F.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-ZOMD.F
$0.13
49.7% Upside
Undervalued
—
—
—
Good
—
—
—
0.0%
August 12, 2026
-3.9x
0.8x
2.6x
86.236 M
42.699 M
2.2%
96.9%
0.1
—
73.5%
Send a message
Valuation • Fair Value

Zomedica Corp (OTC-ZOMD.F) Fair Value by Valuation Model

Compare the primary fair value estimate for Zomedica Corp (OTC-ZOMD.F) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.13

Estimated upside of 49.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.16

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$0.17

Earnings power value estimate.

Comps Fair Value

$0.12

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Zomedica Corp (OTC-ZOMD.F) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Zomedica Corp (OTC-ZOMD.F)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

34.329 M

Current operating scale indicator.

Revenue Forecast

45.33 M

Forward revenue estimate.

EBITDA

-17.077 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Zomedica Corp (OTC-ZOMD.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Zomedica Corp (OTC-ZOMD.F)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-1.33

Higher caution zone on this screen.

Altman Z-Score

0.1

Lower score that deserves closer risk review.

FCF / Net Income

73.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Zomedica Corp (OTC-ZOMD.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Zomedica Corp (OTC-ZOMD.F)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 12, 2026

Days to Earnings

22

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Zomedica Corp (OTC-ZOMD.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Zomedica Corp (OTC-ZOMD.F) Stock Forecast & Technical Outlook

Review Zomedica Corp (OTC-ZOMD.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Zomedica Corp (OTC-ZOMD.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Zomedica Corp (OTC-ZOMD.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Zomedica Corp (OTC-ZOMD.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Zomedica Corp (OTC-ZOMD.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Zomedica Corp (OTC-ZOMD.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Zomedica Corp (OTC-ZOMD.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Zomedica Corp (OTC-ZOMD.F) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Zomedica Corp (OTC-ZOMD.F) Stock FAQ

Quick answers about Zomedica Corp (OTC-ZOMD.F) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.13
Estimated upside 49.7%
Valuation Rating
Undervalued
Estimated upside of 49.7%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Good
Current financial-health read

The current fair value estimate for Zomedica Corp (OTC-ZOMD.F) is $0.13. This implies an estimated upside of 49.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 49.7% versus the current market price.

An analyst price target for Zomedica Corp (OTC-ZOMD.F) is not currently available in the latest data file.

The current financial health read for Zomedica Corp (OTC-ZOMD.F) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Zomedica Corp (OTC-ZOMD.F) is August 12, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Zomedica Corp (OTC-ZOMD.F) is -3.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Zomedica Corp is 86.236 M.

The current enterprise value listed for Zomedica Corp is 42.699 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Zomedica Corp is OTC-ZOMD.F, and the stock is listed on OTC Markets.

Zomedica Corp (OTC-ZOMD.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Zomedica Corp is 2.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Zomedica Corp is 96.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on OTC Markets View more

Essilor International SA (ESLOY) Essilor International SA (ESLOY)
Hoya Corp (HOCPY) Hoya Corp (HOCPY)
Siemens Healthineers AG ADR (SMMNY) Siemens Healthineers AG ADR (SMMNY)
Resmed Inc DRC (RSMDF) Resmed Inc DRC (RSMDF)
Terumo Corp ADR (TRUMY) Terumo Corp ADR (TRUMY)
Straumann Holding AG ADR (SAUHY) Straumann Holding AG ADR (SAUHY)
Sonova Holding AG (SONVY) Sonova Holding AG (SONVY)
Coloplast A (CLPBY) Coloplast A (CLPBY)
Fisher & Paykel Healthcare Ltd (FSPKF) Fisher & Paykel Healthcare Ltd (FSPKF)
Olympus Corp (OLYMY) Olympus Corp (OLYMY)
Demant A/S ADR (WILYY) Demant A/S ADR (WILYY)
Getinge Industrier AB (GNGBY) Getinge Industrier AB (GNGBY)
Sysmex Corp (SSMXY) Sysmex Corp (SSMXY)
ConvaTec Group plc ADR (CNVVY) ConvaTec Group plc ADR (CNVVY)
CochLear Ltd ADR (CHEOY) CochLear Ltd ADR (CHEOY)
Ansell Ltd ADR (ANSLY) Ansell Ltd ADR (ANSLY)
Carl Zeiss Meditec AG ADR (CZMWY) Carl Zeiss Meditec AG ADR (CZMWY)
Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY) Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY)
Elekta AB ADR (EKTAY) Elekta AB ADR (EKTAY)
Nihon Kohden Corp ADR (NHNKY) Nihon Kohden Corp ADR (NHNKY)
Top Glove Corporation Bhd ADR (TGLVY) Top Glove Corporation Bhd ADR (TGLVY)
Cyberdyne Inc ADR (CYBQY) Cyberdyne Inc ADR (CYBQY)
Paxman AB (PXMBF) Paxman AB (PXMBF)
Positron Corp (POSC) Positron Corp (POSC)